Güler TÜRKEŞ, Mustafa YILDIZ, Bülent ÖZTÜRK, Yüksel ALTUNTAŞ, Murat İNNİCE

The effect of doxazosin on arterial distensibility in hypertensive patients with type II diabetes mellitus

Amaç: Bu çalışmada, hipertansif tip II diyabetes mellituslu hastalarda, alfa-1 adrenerjik reseptör blokeri olan doksazosinin arteryel distansibilite üzerine olan etkileri incelendi. Çalışma planı: Çalışmaya, JNC 7. raporuna göre tip 1 veya 2 hipertansiyonu ve tip II diyabeti olan 46 poliklinik hastası (31 kadın, 15 erkek; ort. yaş 58.4±8.3; dağılım 37-70) alındı. Hastaların kullanmakta olduğu antidiyabetik ve antilipidemik ilaçlara ek olarak, sekiz hafta süreyle günde 2 mg dozda doksazosin verildi. Bu süre içinde kan basınçları ve nabızlar iki haftada bir ölçüldü. Kan basıncını düzenlemek için, doksazosin dozu üç hastada (%6.5) ikinci haftada, dört hastada (%8.7) dördüncü haftada 4 mg'ye çıkarıldı. Arteryel distansibilitenin değerlendirilmesi için, karotis-femoral nabız dalga hızı Complior Colson cihazı (Createch Industrie, Fransa) kullanılarak hesaplandı. Bulgular: Tedavi süresi sonunda, tedavi öncesine göre, sistolik kan basıncı (p

Hipertansif tip II diyabetes mellituslu hastalarda doksazosinin arteryel distansibiliteye etkileri

Background: The aim of the present study was to investigate the effect of doxazosin, an alpha-1 adrenergic receptor blocker, on arterial distensibility in hypertensive patients with type II diabetes mellitus. Methods: The study included 46 outpatients (31 females, 15 males; mean age 58.4±8.3 years; range 37 to 70 years) with type II diabetes mellitus and stage 1 or 2 hypertension according to the JNC 7 report. In addition to antidiabetic and antilipidemic drugs, the patients were given doxazosin 2 mg daily for eight weeks, during which measurements of blood pressure and pulse were made every two weeks. To regulate blood pressure, the dose of doxazosin was increased to 4 mg in the second week in three patients (6.5%), and in the fourth week in four patients (8.7%). Arterial distensibility was assessed by measuring carotidfemoral pulse wave velocity with an automatic device (Complior Colson, Createch Industrie, France). Results: Compared to pretreatment values, significant decreases occurred at the end of eight weeks in the following parameters: systolic blood pressure (p

PDF

___

1. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988;78:941-50.
2. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001;19:813-8.
3. Tedeschi C, Guarini P, Giordano G, Messina V, Cicatiello AM, Iovino L, et al. Effects of nicardipine on intimal-medial thickness and arterial distensibility in hypertensive patients.Preliminary results after 6 months. Int Angiol 1993; 12:344-7.
4. Yildiz M, Ozturk B, Turkes G, Innice M, Koc G, Şeber S, et al. The effect of doxazosin on arterial compliance and microalbuminuria on hypertensive and normotensive NIDDM patients. J Endocrinol Invest 2000;23(Suppl 7):50.
5. Leren P. The cardiovascular effects of alpha-receptor blocking agents.J Hypertens Suppl 1992; 10:S11-4.
6. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 2001;14:91-7.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
9. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485-90.
10. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries. Arterioscler Thromb 1993; 13:90-7.
11. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med 1992;9:114-9.
12. O'Rourke MR The arterial pulse in health and disease. Am Heart J 1971;82:687-702.
13. Sa Cunha R, Pannier B, Benetos A, Siche JP, London GM, Mallion JM, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15(12 Pt 1): 1423-30.
14. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14:897-901.
15. Harmse DP. Clinical experience with doxazosin in general medical practice in The Netherlands. Am Heart J 1991;121(1 Pt 2):341-5.
16. Blankenhorn DH, Hodis HN. Atherosclerosis-reversal with therapy. West J Med 1993; 159:172-9.
17. Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996;45:1253-8.
18. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr Hypertens Rep 2001;3:281-8.
19. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995;48:217-23.
20. Safar ME, Laurent SL, Bouthier JD, London GM, Mimran AR. Effect of converting enzyme inhibitors on hypertensive large arteries in humans. J Hypertens Suppl 1986;4:S285-9.
21. Laurent S, Arcaro G, Benetos A, Lafleche A, Hoeks A, Safar M. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. J Cardiovasc Pharmacol 1992;19:641-9.
22. Kuschinsky W, Wahl M. Alpha-receptor stimulation by endogenous and exogenous norepinephrine and blockade by phentolamine in pial arteries of cats. Circ Res 1975;37; 168-74.
23. Olivetti G, Anversa P, Melissari M, Loud AV. Morphometry of medial hypertrophy in the rat thoracic aorta. Lab Invest 1980;42:559-65.
24. Pannier B, Safar M. Effects of rilmenidine on arterial parameters in essential arterial hypertension. [Article in French] Arch Mai Coeur Vaiss 1989;82 Spec No 5:47-51.
25. Laurent S, Lacolley P, Billaud E, Arcaro G, Safar M. Large and small forearm arteries of essential hypertensives are less reactive to angiotensin II than to noradrenaline. J Hypertens Suppl 1989;7:S76-7.
26. Levy BI, Benessiano J, Poitevin P, Safar ME. Endotheliumdependent mechanical properties of the carotid artery in WKY and SHR. Role of angiotensin converting enzyme inhibition. Circ Res 1990;66:321-8.